Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Sep 23;105(6):e213912.
doi: 10.1212/WNL.0000000000213912. Epub 2025 Sep 2.

Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic

Affiliations
Observational Study

Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic

Brian Renner et al. Neurology. .

Abstract

Background and objectives: Paramagnetic rim lesions (PRLs) are a well-established imaging biomarker of chronic active multiple sclerosis (MS) lesions. PRLs have been shown to be highly specific for MS (∼90% specificity), and their prevalence has been estimated to be approximately 50% in patients with clinically established diagnoses of MS. In this study, we evaluated the frequency and diagnostic value of PRLs in patients at first clinical presentation.

Methods: Adults age 18-64 years presenting with clinical symptoms or radiologic suspicion of demyelinating disease referred to academic specialty MS centers without a definitive diagnosis were prospectively enrolled in a multicenter, cross-sectional, observational study. Phase images from high-resolution 3D echo-planar imaging were acquired on 3-tesla brain MRI and evaluated for PRLs by 3 independent raters, blinded to diagnosis, with adjudication from a fourth expert rater. Diagnostic performance of PRLs for a diagnosis of MS using the 2017 McDonald criteria as gold standard was evaluated using diagnostic thresholds based on the presence of at least 1 PRL (≥1 PRL) or at least 2 PRLs (≥2 PRLs).

Results: Seventy-eight participants were analyzed (mean age, years [range]: 45.0 [18-64] female sex n = 55 [71%]); a total of 124 PRLs were counted in 36 (46%) of the 78 participants (median: 3 PRLs; range: 1-9 PRLs). Thirty-two (89%) of the 36 PRL-positive participants fulfilled 2017 McDonald criteria, and the remaining 4 (11%) had an alternate diagnosis. The presence of ≥1 PRL had a sensitivity of 0.86 (95% CI 0.71-0.95) and a specificity of 0.90 (95% CI 0.77-0.97). For ≥2 PRLs, specificity increased to 0.95 (95% CI 0.83-0.99), whereas sensitivity decreased to 0.59 (95% CI 0.42-0.75). For participants with MS, shorter duration from initial symptom onset was associated with higher probability of having PRLs, with the odds of being PRL positive (≥1 PRL) increasing by 28% for every 1 year decrease from symptom onset (odds ratio 1.28 per year, 95% CI 1.03-1.59, p = 0.03).

Discussion: PRLs are highly prevalent early in patients with MS at the time of first clinical presentation and can differentiate MS from mimics with high accuracy.

PubMed Disclaimer

Conflict of interest statement

M. Absinta reports speaker honoraria and/or consulting compensation from Sanofi-Genzyme, Biogen, Roche, Abata Therapeutics, Immunic Therapeutics, and GSK. P.R. Rodrigues, M. Ramos, and V. Prchkovska are employees of QMENTA Inc. C.J. Azevedo has received personal compensation for consulting from Zenas Biopharma, Genentech, EMD Serono, Alexion Pharmaceuticals, and Sanofi Genzyme; and research support from the National Multiple Sclerosis Society. A. Bar-Or has received consulting fees for scientific advisory boards for Abata, Atara Biotherapeutics, Biogen Idec, BMS/Celgene/Receptos, Immunic, Janssen/Actelion, Merck/EMD Serono, Novartis, Roche/Genentech, and Sanofi-Genzyme; and sponsored research agreements with Biogen Idec, Novartis, EMD Serono, and Roche/Genentech. P.A. Calabresi has received consulting fees from Lilly and Novartis; and is a PI on grant to JHU from Genentech. B.A.C. Cree has received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, Biogen, Boston Pharma, EMD Serono, Hexal/Sandoz, Horizon, Immunic AG, Kyverna, Neuron23, Novartis, Sanofi, Siemens, and TG Therapeutics; and received research support from Genentech and Kyverna. L. Freeman reports advisory board participation (Genentech, Novartis, Celgene); consulting (EMD Serono, Celgene, Biogen); and program sponsorship (Biogen, EMD Serono). R.G. Henry has received personal compensation for consulting from Roche, Novartis, Sanofi, and QIA Consulting; and research funding from Roche/Genentech and Atara. E.E. Longbrake has received consulting fees from Genentech, Genzyme, Alexion, Biogen, EMD/Serono, Celegene/Bristol Myers Squibb, TG Therapeutics, and Novartis; and research support from Genentech and Biogen. J. Oh has received research support from Biogen-Idec and Roche; and personal compensation for consulting from Amgen, EMD-Serono, Eli-Lilly, Sanofi-Genzyme, Biogen-Idec, Roche, and Novartis. D. Pelletier has received consulting compensation from EMD-Serono, Sanofi Genzyme, Roche, and Novartis. R.D. Samudralwar reports advisory board participation (Biogen, EMD Serono, Sanofi Genzyme) and consulting (EMD Serono, Biogen). E.S. Sotirchos reports consulting fees for scientific advisory boards from Alexion, Amgen, TG Therapeutics, and Roche/Genentech; and speaker honoraria from Alexion. N.L. Sicotte reports research support from the NIH, the National Multiple Sclerosis Society, the Patient Centered Outcomes Research Institute, and the Race to Erase MS Foundation. A.J. Solomon reports consulting or advisory board participation (Genentech, Octave Bioscience, Horizon Therapeutics, Kiniksa Pharmaceuticals, and TG Therapeutics); nonpromotional speaking (EMD Serono); research funding (Bristol Meyers Squibb); and contract research (Sanofi, Actelion, Genentech, and Novartis). R.T. Shinohara has received funding for work on this project from the NIH (R01MH112847, R01MH123550, R01NS112274, R01 NS060910, and K02NS109340) and the National Multiple Sclerosis Society (RG-1707-28,586); and personal compensation for reviewer duties from the American Medical Association and consulting for Octave Bioscience. D.S. Reich is supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke (Z01 NS003119); and by additional research support from Abata Therapeutics and Sanofi. D. Ontaneda reports research support from the NIH, the National Multiple Sclerosis Society, the Patient Centered Outcomes Research Institute, the Race to Erase MS Foundation, Genentech, and Novartis; and consulting fees from Biogen Idec, Genentech/Roche, Novartis, and Contineum Therapeutics. P. Sati reports research support from the NIH, the National Multiple Sclerosis Society, the Department of Defense, Biogen Idec., and the Erwin Rautenberg Foundation; and consulting fees from Sanofi. All other authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Figures

Figure 1
Figure 1. Representative Example of a Paramagnetic Rim Lesion
Red arrows point to the same lesion shown on 4 different contrast images: phase-EPI, T2*-EPI, T2-FLAIR, and T1-GRE post-Gd. The lesion is focal and hyperintense on T2-FLAIR, nonenhancing on T1-GRE post-Gd, and has a hypointense rim on both phase-EPI and T2*-EPI phase-EPI = T2*-weighted echo-planar imaging (phase reconstruction), T2*-EPI = T2*-weighted echo-planar imaging (magnitude reconstruction), T2-FLAIR = T2-weighted fluid-attenuated inversion recovery, T1-GRE post-gd = T1-weighted gradient-recalled echo after injection of gadolinium contrast agent.
Figure 2
Figure 2. Flowchart Summary of Participant Stratification in the Primary Analysis
CIS = clinically isolated syndrome; DMT = disease-modifying therapy; MS = multiple sclerosis; Gd = gadolinium-based contrast agent; RIS = radiologically isolated syndrome.
Figure 3
Figure 3. Distribution of PRL Across all the Participants Included in the Primary Analysis (n = 78)
MC2017 = McDonald 2017 Criteria; PRL = paramagnetic rim lesion.
Figure 4
Figure 4. ROC Curve for the Presence of PRL (≥1 PRL) Relative to MS Diagnosis With 2017 McDonald Criteria
The area under the ROC curve is 0.88 (95% CI 0.81–0.96). PRL = paramagnetic rim lesion; ROC = receiver operating characteristic.

Comment in

References

    1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169-180. doi: 10.1056/NEJMra1401483 - DOI - PMC - PubMed
    1. Solomon AJ, Kaisey M, Krieger SC, et al. Multiple sclerosis diagnosis: knowledge gaps and opportunities for educational intervention in neurologists in the United States. Mult Scler J. 2022;28(8):1248-1256. doi: 10.1177/13524585211048401 - DOI - PMC - PubMed
    1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. doi: 10.1016/s1474-4422(17)30470-2 - DOI - PubMed
    1. Filippi M, Preziosa P, Meani A, et al. Performance of the 2017 and 2010 revised McDonald criteria in predicting MS diagnosis after a clinically isolated syndrome: a MAGNIMS study. Neurology. 2022;98(1):e1-e14. doi: 10.1212/wnl.0000000000013016 - DOI - PubMed
    1. Kaisey M, Solomon AJ, Luu M, Giesser BS, Sicotte NL. Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers. Mult Scler Relat Disord. 2019;30:51-56. doi: 10.1016/j.msard.2019.01.048 - DOI - PubMed

Publication types